青霉胺

Penicillamine is primarily used in the treatment of Wilson's disease, a genetic disorder that causes copper accumulation in the body.
铜胺是主要用于治疗威尔逊病的一种药物，这是一种导致体内铜元素积累的遗传性疾病。
In rheumatoid arthritis patients, penicillamine helps to reduce pain and swelling by decreasing the body's production of collagenase.
在类风湿关节炎患者中，铜胺有助于通过减少体内胶原酶的产生来减轻疼痛和肿胀。
The drug penicillamine is also known for its chelating properties which help remove excess heavy metals from the body.
药物铜胺也因其螯合特性而知名，这种特性有助于从体内去除多余的重金属。
Long-term use of penicillamine can lead to side effects such as nausea, mouth ulcers, and a weakened immune system.
长期使用铜胺可能会导致恶心、口腔溃疡以及免疫系统减弱等副作用。
Penicillamine therapy should be closely monitored by a healthcare professional due to its potential for serious adverse reactions.
由于铜胺疗法有可能引发严重不良反应，因此应由医疗专业人员密切监控。
Patients with cystinuria may benefit from taking penicillamine as it aids in breaking down and excreting excess cystine in urine.
含胱氨酸尿症患者可能受益于服用铜胺，因为它有助于分解并排出尿液中过量的胱氨酸。
Due to its ability to affect connective tissue turnover, penicillamine has been tried experimentally in the treatment of scleroderma.
由于其影响结缔组织周转的能力，铜胺在硬皮病治疗中进行了实验性尝试。
A patient must not receive penicillamine if they have a known allergy to penicillin antibiotics.
如果患者已知对青霉素抗生素过敏，则不应接受铜胺治疗。
Penicillamine is classified as a disease-modifying antirheumatic drug (DMARD) because of its impact on the progression of rheumatoid arthritis.
铜胺被归类为一种改变疾病的抗风湿药（DMARD），因为其对类风湿关节炎进展的影响。
When initiating penicillamine therapy, gradual dose titration is essential to minimize the risk of severe side effects like kidney stones or myasthenia gravis.
在开始铜胺疗法时，逐步调整剂量至关重要，以尽量减少肾结石或重症肌无力等严重副作用的风险。